LEUVEN MINDGATE

Epilog Technology Improves Diagnosis of Epilepsy using Automated EEG Analysis


Epilepsy, a condition characterized by uncontrolled brain activity, is a complex pathology that occurs in many different forms. The screening and treatment of epilepsy is a difficult and time-consuming process. Moreover, about one third of the patients suffer from so-called pharmaco-resistant epilepsy, meaning that they cannot be treated with medication. Brain surgery is currently the best treatment for these patients, however, hospitals are faced with long waiting lists and limited resources that result in treatment delays of up to a year or more. 
“The electroencephalogram, or EEG, is one of the cornerstone techniques to diagnose epilepsy,” stated Gregor Strobbe, co-founder of Epilog. ”Unfortunately, the interpretation of EEG data is a labor-intensive and subjective process. Epilog’s technology can automatically detect epileptic phenomena in the EEG recordings and localize their origin in the patient’s brain. The doctor can use this information to make the most well-informed treatment decision, such as medication or brain surgery.” 

Using the Epilog service is easy: Epilog receives the EEG-data of the patient, analyzes the data and provides a standardized report with the results. The platform architecture is entirely cloud-based, allowing time-efficient detection and 3D visualization of the epileptic phenomena. Furthermore, the Epilog services are user-friendly and overcome the need for hospitals to invest in technical know-how and computation power. To-date, 75 test cases have been offered to Epilog and the results have been very promising. In a retrospective study it has been shown that Epilog’s technology achieves a sensitivity of 86% to localize the epileptic focus in the patient’s brain.

“The reliablity of our results stems from more than 10 years of research in optimizing EEG analysis methods at Ghent University,” explained Pieter van Mierlo, co-founder of Epilog. “Thanks to our close collaboration with Ghent University Hospital, we have gained a multitude of insight. Currently, physicians are testing our solution in hospitals across Europe and we anticipate being a key technology that supports their treatment of epilepsy patients.“ 

With the financial support and guidance of investors Walter Mastelinck, founder and CEO of Transics, and Patrick Keereman, CEO of Molecubes, Epilog has now started commercializing its software. CE and FDA labeling is also in progress, to allow introduction into the international epilepsy market.

“Epilog is at the precipice of a new generation of technologies that improve neurological disease diagnosis,” commented Vincent Keeremen, co-founder of Epilog. “Our intention is to use our platform to tackle other applications in neurology. Early detection of neurodegenerative disorders such as Alzheimer’s disease, or the prediction of the efficacy of neurological medication may be feasible and therefore, advance treatment.”

About Epilog

Website: https://epilog.care/
Twitter: https://twitter.com/e_p_i_l_o_g
Facebook: https://www.facebook.com/EpilogEegExpertise
Linkedin: https://www.linkedin.com/company/epilog-eeg-expertise

About imec

Imec is the world-leading research and innovation hub in nano-electronics and digital technologies. The combination of our widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes us unique. By leveraging our world-class infrastructure and local and global ecosystem of partners across a multitude of industries, we create groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. 
As a trusted partner for companies, start-ups and universities we bring together close to 3,500 brilliant minds from over 70 nationalities. Imec is headquartered in Leuven, Belgium and also has distributed R&D groups at a number of Flemish universities, in the Netherlands, Taiwan, USA, China, and offices in India and Japan. In 2015, imec's revenue (P&L) totaled 415 million euro and of iMinds which is integrated in imec as of September 21, 2016 52 million euro. Further information on imec can be found at http://www.imec.be/
Imec is a registered trademark for the activities of IMEC International (a legal entity set up under Belgian law as a "stichting van openbaar nut”), imec Belgium (IMEC vzw supported by the Flemish Government), imec the Netherlands (Stichting IMEC Nederland, part of Holst Centre which is supported by the Dutch Government), imec Taiwan (IMEC Taiwan Co.) and imec China (IMEC Microelectronics (Shanghai) Co. Ltd.) and imec India (Imec India Private Limited), imec Florida (IMEC USA nanoelectronics design center).

Contact:

Epilog: Gregor Strobbe, CEO Epilog NV, +32484777651 // gregor@epilog.care
Imec: Hanne Degans, Press Officer, +32 16 28 17 69 // +32 486 06 51 75 // Hanne.Degans@imec.be

 

 

Subscribe to our newsletter

Stay tuned and get our news in your inbox: subscribe here.

Keep me informed
Follow us